Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15679459 | 1.00 | SYK (1.00) | SYKKDRKCNH2 | |
| SCHEMBL14241434 | 1.00 | SYK (1.00) | SYKKDRKCNH2 | |
| SCHEMBL14242146 | 0.95 | SYK (0.90) | SYKKDRKCNH2 | |
| SCHEMBL19496255 | 0.91 | SYK (0.83) | SYKKDRKCNH2 | |
| SCHEMBL19495470 | 0.91 | SYK (0.83) | SYKKDRKCNH2 | |
| SCHEMBL15654928 | 0.90 | SYK (0.82) | SYKKDRKCNH2 | |
| SCHEMBL19496479 | 0.90 | SYK (0.82) | SYKKDRKCNH2 | |
| SCHEMBL14242053 | 0.90 | SYK (0.82) | SYKKDRKCNH2 | |
| SCHEMBL14241466 | 0.90 | SYK (0.82) | SYKKDRKCNH2 | |
| SCHEMBL14241722 | 0.87 | SYK (1.00) | SYKKDRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-08-21 | — | — | US | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED | 2016-11-10 | — | — | US | disclosed |
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED | 2016-11-10 | — | — | US | disclosed |
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED | 2016-11-10 | — | — | US | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-05-01 | — | — | US | disclosed |
| WO-2012167733-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012167423-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885KDR 52/4885KCNH2 1812/4885 |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | SYK, BTK, TYRO3 | SYK 1/4885KDR 53/4885KCNH2 1710/4885 |
| US-20140121200-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885KDR 55/4885KCNH2 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.